What Have We Learned from the Shortening of Treatment for Drug-sensitive TB?

Date:

November 20, 2014 (All Day)

Dr. Richard Chaisson and Dr. Eric Nuermberger talk about what has been learned from recent phase 2 and phase 3 trials of shortening the treatment for drug-sensitive tuberculosis. 

Video/Audio/Slides

Audio-only/Slides

Projects

Scale-up and implementation of TB diagnostics...

We are evaluating the implementation, cost-effectiveness, and potential epidemiological impact of scaling up Xpert across 19...

Read More

Options for Patient-Centered Delivery of...

This individually randomized trial is evaluating the relative effectiveness of self-administered therapy, directly observed...

Read More

Evaluating an automated system for...

We are evaluating the accuracy and cost-effectiveness of TBDx, an automated digital microscopy system, as a screening test to...

Read More

TBM-KIDS (India)

A phase 2 clinical trial of optimized treatment for pediatric tuberculous meningitis in India and Malawi

Read More

A Blueprint for Success: Understanding the...

We are using a combination of statistical analysis and transmission modeling, in collaboration with the NYC Dept of Health &...

Read More